First Patient Enrolled in Global Ph 3 Trial of Cadonilimab vs Nivolumab in 1L Gastric Cancer October 6, 2026
First patient dosed with LNK001 in Ph 1 study in patients with advanced or metastatic clear cell RCC October 6, 2026
Second Patient treated in the Fifth Cohort of Ovarian Cancer FSHR-targeted CAR-T Clinical Trial October 6, 2026
IDMC Recommends Continued Ph 2 Development of IMNN-001 Following Favorable Safety Review October 1, 2026
Target enrollment achieved in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma September 22, 2026
Ph 2 ALISCA®-Lung2 Trial of Alisertib + Paclitaxel Initiated for Patients with Advanced SCLC September 22, 2026
First Patient dosed in Ph 1 Trial of CBX-663 for Treatment of Multiple Hematologic and Solid Malignancies September 16, 2026
US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit with HCB101 September 16, 2026
DSMB recommends termination of Ph 2 trial of adjuvant BNT122-01 in patients with circulating tumor DNA-positive, surgically resected Stage II/III CRC September 2, 2026
First Patient Dosed in Ph 3 Study of ASP2138 in CLDN18.2+ve and HER2-neg locally advanced unresectable or metastatic GEJ adenocarcinoma September 2, 2026
First patient dosed in Ph 1 KOALA trial of KMCAR™ T-cell therapy in patients with R/R kappa-restricted multiple myeloma September 2, 2026
First patient dosed in Ph 1 trial of ABSK211 for advanced solid tumors with KRAS alterations September 2, 2026
IDMC recommends to continue patient enrolment in Ph 1 ZIMA-101 trial in solid tumor patients August 25, 2026
First Patient Dosed in MODeFIRe-1 Ph 2 Study of MRT-2359 + Apalutamide in Patients with AR Mutation-Positive Metastatic CRPC August 25, 2026
SUPRAME topline data disclosure for the final PFS analysis expected in H1 2027, followed by BLA submission in 2027 August 25, 2026
Enrollment opens in Ph 1 Clinical Trial Evaluating Treatment of Malignant Brain Tumors with APTN-101 August 25, 2026
